White House Issues Executive Orders Impacting the Life Sciences
President Trump officially signed four Executive Orders (EOs) last Friday. The EOs target four policy areas: drug importation, 340B, rebate rule, and most concerning – IPI/Most Favored Nation (MFN). The EO for the IPI/MFN proposal has yet to be released, but according to details discussed at the press conference, it will not go into effect until August 24th to allow companies to “present a counter proposal” in the words of the President. (The final EO, once posted, will be available here.)
CLSA is extremely concerned with the IPI/MFN proposal and is working to implement a multi-channel strategy in response. We are working closely with our national partners at BIO and PhRMA to highlight the devastating impacts this proposal would have on innovation, especially for rare or orphan drugs and novel therapies.
CLSA issued the following statement following Friday’s announcement, and will continue to advocate for innovation and protection of our industry from harmful policies.